SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: ADVENTRX Pharmaceuticals, Inc. (Note: Request metadata listed "Savara Inc," but the filing text identifies the registrant as ADVENTRX Pharmaceuticals, Inc.)
Filing Date: November 9, 2006
Reporting Period: Quarterly period ended September 30, 2006
Event: Announcement of financial results via press release.
Key Financial Metrics
The filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. The text of this Form 8-K does not provide specific values for:
- Revenue
- Profit or Loss
- Cash Flow
- Margins
- Debt or Liquidity positions
The filing text does not provide a clear value for these metrics; they are contained within the referenced Exhibit 99.1.
Material Changes
No specific material changes, comparative figures, or year-over-year analysis are detailed within the body of this Form 8-K. The document solely confirms the issuance of results for the quarter ended September 30, 2006.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or descriptions of unusual items. These details are presumed to be in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1).
- Confirm the company name discrepancy between the request metadata ("Savara Inc") and the filing ("ADVENTRX Pharmaceuticals, Inc").
- Review the press release for any updates on clinical trial progress or product development, typical for pharmaceutical companies of this era.
- Check for any subsequent filings regarding the company's liquidity status post-September 2006.